Biochanin A / GSK‐3β Cancer Research Results

BCA, Biochanin A: Click to Expand ⟱
Features:
Biochanin A is a O-methylated isoflavone.
Found in soy, alfalfa sprouts, peanuts, chickpeas and other legumes.
Inhibits fatty acid amide hydrolase.
-gut/metabolic precursor to genistein

Biochanin A — Biochanin A is a naturally occurring O-methylated isoflavone phytochemical and phytoestrogen found mainly in red clover and other legumes including chickpea, soybean, peanut, and alfalfa. It is best classified as a small-molecule dietary isoflavone / nutraceutical lead rather than an approved oncology drug. Standard abbreviations include BCA and Bio-A. In biological systems it can act both as the parent compound and as a metabolic precursor to genistein and related conjugates, which is important when interpreting systemic effects. In cancer research, Biochanin A is primarily a multi-target preclinical antitumor candidate with anti-proliferative, pro-apoptotic, anti-EMT, and immune-evasion-limiting effects, but translation is constrained by low oral bioavailability, extensive metabolism, estrogenic context dependence, and limited human efficacy data.

main ingredients in many types of supplements used to alleviate postmenopausal symptoms in women

Primary mechanisms (ranked):

  1. EMT suppression centered on ZEB1 downregulation, with associated E-cadherin increase, N-cadherin decrease, reduced invasion/migration, and lower metastatic competence.
  2. Immune-evasion attenuation via ZEB1-linked PD-L1 downregulation in colorectal cancer models.
  3. Mitochondria-associated intrinsic apoptosis with caspase activation, PARP cleavage, Bax/Bcl-2 shift, and cell-cycle arrest in multiple tumor models.
  4. Mitogenic signaling suppression, variably involving PI3K/Akt, ERK/MAPK, NF-κB, and related growth/survival pathways depending on model.
  5. Chemosensitization / resistance modulation, especially in ZEB1-high settings and selected combination regimens.
  6. Redox modulation is context-dependent rather than uniformly antioxidant; some cancer models show ROS increase contributing to apoptosis, while in other settings anti-inflammatory / antioxidant signaling predominates.
  7. FAAH inhibition is a recognized biochemical activity of Biochanin A but is not currently a core cancer mechanism.

Bioavailability / PK relevance: Oral translation is limited by poor solubility, poor oral absorption, extensive intestinal/hepatic phase I–II metabolism, high clearance, enterohepatic cycling, and rapid conversion to conjugates and downstream isoflavone metabolites including genistein. As a result, formulation strategy is often mechanistically relevant to outcome.

In-vitro vs systemic exposure relevance: Many anticancer in-vitro studies use tens of micromolar concentrations, often around 20–100 μM, which likely exceed routine free systemic exposure achievable from ordinary oral intake of unformulated Biochanin A. Therefore, direct concentration-driven antitumor claims should be interpreted cautiously unless supported by formulation, tissue-delivery, or metabolite data.

Clinical evidence status: Preclinical. There is substantial in-vitro and animal antitumor literature, but human oncology evidence remains very limited, with no established role as a standard anticancer therapy. Human deployment is mainly as part of dietary / red-clover isoflavone supplement use rather than cancer-directed drug treatment.

Mechanistic table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ZEB1 EMT axis ↓ ZEB1, ↓ EMT, ↓ migration, ↓ invasion ↔ / not well defined G Anti-metastatic state shift Most coherent cancer-specific axis across current evidence; especially relevant in colorectal and lung adenocarcinoma models.
2 PD-L1 immune-evasion signaling ↓ PD-L1 ↔ G Reduced immune escape potential Best supported in CRC through ZEB1-linked regulation; mechanistically meaningful but not yet clinically validated as an immunotherapy adjunct.
3 Intrinsic apoptosis program ↑ caspases, ↑ PARP cleavage, ↑ Bax/Bcl-2 ratio, ↑ apoptosis ↔ / selective in some models R/G Cytotoxic / cytostatic tumor control Common downstream output across multiple cancer models; likely integrates mitochondrial stress and growth-signal suppression.
4 Mitochondria / redox stress ↑ ROS (context-dependent), ↑ oxidative stress, ↓ mitochondrial fitness ↔ / potential protection in non-cancer inflammatory settings R/G Facilitates apoptosis in susceptible tumors ROS is not uniformly directional across all literature; in cancer it can rise enough to support death signaling, whereas outside cancer Biochanin A is often described as antioxidant.
5 PI3K Akt survival signaling ↓ PI3K/Akt (model-dependent) ↔ R/G Reduced survival / proliferation Frequently reported in breast and other tumor models, but less specific than the ZEB1-centered mechanism.
6 ERK MAPK proliferation signaling ↓ ERK (model-dependent) ↔ R/G Anti-proliferative effect Consistent with Nestronics indexing and broader preclinical literature, but not universal across tumor types.
7 Cell-cycle machinery ↓ cyclins / CDKs, arrest ↑ ↔ G Cytostasis preceding apoptosis Phase specificity varies by model; contributes to lower clonogenicity and slower tumor expansion.
8 Chemosensitization ↑ cisplatin sensitivity, ↓ resistance traits ↔ G Adjunct leverage Best-supported adjunct signal is ZEB1-linked sensitization in lung adenocarcinoma; combination effects are promising but still preclinical.
9 FAAH and non-oncology biochemical activity ↔ / indirect ↔ R/G Not a core cancer effect Real biochemical property, but currently peripheral to anticancer ranking.
10 Clinical Translation Constraint Low free exposure, extensive metabolism, estrogenic context, interaction risk Potential endocrine / PK relevance G Limits direct monotherapy translation Common in-vitro doses likely exceed achievable free systemic exposure of unformulated oral Biochanin A; formulation or metabolite-aware development is likely required.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr

For Alzheimer’s

Biochanin A — Biochanin A is a naturally occurring O-methylated isoflavone phytoestrogen found mainly in red clover and other legumes. It is best classified in the AD context as a preclinical neuroprotective small molecule / nutraceutical lead rather than an approved CNS drug. Standard abbreviations include BCA and Bio-A. Current Alzheimer’s relevance is based on cell, mouse, and review-level evidence suggesting anti-amyloid, anti-apoptotic, anti-neuroinflammatory, antioxidant-response, mitochondrial-protective, and cholinergic-supportive actions. Its translational interpretation is limited by sparse brain PK data, likely extensive metabolism, and the fact that many mechanistic studies use concentrations above typical dietary exposure.

Primary mechanisms (ranked):

  1. Mitochondrial protection with suppression of Aβ-triggered intrinsic apoptosis, including preservation of mitochondrial membrane potential and improvement of Bcl-2/Bax balance.
  2. Neuroinflammation reduction through suppression of pro-inflammatory mediators and downregulation of NF-κB-linked signaling.
  3. Antioxidant-response support, including Nrf2-linked cytoprotection and reduction of oxidative stress markers in preclinical CNS models.
  4. Cholinergic support, with reduced whole-brain acetylcholinesterase activity and improved behavioral performance in scopolamine and aged-mouse models.
  5. Anti-amyloid effect, reported mainly as reduced Aβ-associated injury and, in reviews, reduced Aβ burden in experimental systems.
  6. Blood-brain barrier support is plausible and preclinically supported in ischemia-reperfusion models, but this is not yet AD-specific proof.

Bioavailability / PK relevance: CNS translation remains uncertain because Biochanin A has generally poor oral bioavailability and substantial metabolism; whether parent Biochanin A, its conjugates, or downstream metabolites mediate brain effects remains incompletely resolved.

In-vitro vs systemic exposure relevance: Many neuroprotection studies use approximately 10–100 μM in vitro, including Aβ-PC12 work up to 100 μM, which likely exceeds routine free brain exposure from ordinary oral intake. Therefore, direct concentration-driven neuroprotective claims should be interpreted cautiously.

Clinical evidence status: Preclinical. I did not locate established AD clinical trials showing therapeutic efficacy of Biochanin A itself. Current support comes from mechanistic reviews, cell systems, and animal models rather than human efficacy studies.

AD mechanistic table

Rank Pathway / Axis Modulation TSF Primary Effect Notes / Interpretation
1 Mitochondrial apoptosis control ↓ cytochrome c, ↓ Puma, ↑ Bcl-2/Bax, ↑ Bcl-xL/Bax, ↓ caspase-9, ↓ caspase-3 R/G Neuronal survival support Best direct AD-relevant mechanistic evidence comes from Aβ25–35-treated PC12 cells, where Biochanin A preserved mitochondrial function and reduced apoptosis.
2 Mitochondrial membrane potential ↑ MMP stability R Limits Aβ-linked mitochondrial collapse A central proximal mechanism in the PC12 amyloid-toxicity model.
3 Neuroinflammation and NF-κB-linked signaling ↓ TNF-α, ↓ IL-1β, ↓ NO, ↓ inflammatory tone G Reduces inflammatory neuronal stress Supported mainly by reviews and broader neuroprotection literature; likely important but less directly demonstrated in AD-specific human systems.
4 Nrf2 antioxidant-response axis ↑ Nrf2 signaling, ↑ GSH/SOD/CAT, ↓ oxidative stress G Cytoprotective redox buffering Mechanistically plausible and supported in CNS disease models; AD relevance is still preclinical and partly inferential.
5 Aβ-associated neuronal injury ↓ Aβ toxicity, ↓ LDH leakage, ↑ viability R/G Attenuates amyloid-linked cell damage Strongly supported in the Aβ25–35 PC12 model; evidence for lowering in vivo plaque burden is review-level rather than established clinical fact.
6 Cholinergic axis ↓ acetylcholinesterase G Supports memory-related neurotransmission Observed in scopolamine-treated and aged mice together with behavioral improvement, but this is not equivalent to approved ChE inhibitor efficacy.
7 Behavioral and memory phenotype ↑ cognitive performance G Functional preclinical improvement Behavioral benefit is reported in mouse dementia-like models, which strengthens relevance but remains model-dependent.
8 Blood-brain barrier support ↑ BBB integrity G Potential vascular-neuroprotective support Supported in ischemia-reperfusion studies, not yet a core AD mechanism but potentially relevant to mixed neurovascular pathology.
9 Clinical Translation Constraint ↓ direct translatability G Limits therapeutic certainty Key constraints are low oral bioavailability, uncertain brain exposure of parent compound, likely metabolite contribution, estrogenic context, and lack of convincing human AD efficacy data.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr
GSK‐3β, Glycogen synthase kinase (GSK)3β: Click to Expand ⟱
Source:
Type:
GSK3β is a crucial member of the Wnt/β-catenin-, hedgehog (Hh)-, notch- and c-myc-mediated major pro-oncogenic pathways, while also being a negative regulator of epithelial–mesenchymal transition (EMT). Accumulating evidence defines GSK3β as a potential therapeutic target in cancer, thus encouraging the development of GSK3β inhibitors for cancer treatment.
Glycogen synthase kinase 3 beta (GSK-3β) is a serine/threonine kinase that plays a crucial role in various cellular processes, including cell proliferation, differentiation, and apoptosis. Its expression and activity have been implicated in several types of cancer, often with varying prognostic implications.

In many cancers, decreased GSK-3β activity is associated with poor prognosis, while in others, increased activity may correlate with aggressive disease.


Scientific Papers found: Click to Expand⟱
5633- BCA,    Mechanisms Behind the Pharmacological Application of Biochanin-A: A review
- Review, Var, NA - Review, AD, NA
*AntiDiabetic↑, *neuroP↑, *toxicity↓, *CYP19↓, p‑Akt↓, mTOR↓, TumCCA↑, P21↑, Casp3↑, Bcl-2↑, Apoptosis↑, E-cadherin↓, TumMeta↓, eff↑, GSK‐3β↓, β-catenin/ZEB1↓, RadioS↑, ROS↑, Casp1↑, MMP2↓, MMP9↓, EGFR↓, ChemoSen↑, PI3K↓, MMPs↓, Hif1a↓, VEGF↓, *ROS↓, *Obesity↓, *cardioP↑, *NRF2↑, *NF-kB↓, *Inflam↓, *lipid-P↓, *hepatoP↑, *AST↓, *ALP↓, *Bacteria↓, *neuroP↑, *SOD↑, *GPx↑, *AChE↓, *BACE↓, *memory↑, *BioAv↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Cell Death ⓘ

p‑Akt↓, 1,   Apoptosis↑, 1,   Bcl-2↑, 1,   Casp1↑, 1,   Casp3↑, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 1,   mTOR↓, 1,   PI3K↓, 1,  

Migration ⓘ

E-cadherin↓, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 1,   TumMeta↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 1,   RadioS↑, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,  
Total Targets: 24

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

GPx↑, 1,   lipid-P↓, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,   NF-kB↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,  

Protein Aggregation ⓘ

BACE↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CYP19↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  

Clinical Biomarkers ⓘ

ALP↓, 1,   AST↓, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cardioP↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 2,   Obesity↓, 1,   toxicity↓, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 21

Scientific Paper Hit Count for: GSK‐3β, Glycogen synthase kinase (GSK)3β
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:45  Target#:385  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page